Vir and Alnylam Expand their 2017 License Agreement to Target COVID-19

 Vir and Alnylam Expand their 2017 License Agreement to Target COVID-19

Vir and Alnylam Expand their 2017 License Agreement to Target COVID-19

Shots:

  • The companies expand their existing collaboration to develop & commercialize RNAi therapies targeting SARS-CoV-2 utilizing Alnylam’s advances in lung delivery of novel conjugates of siRNA along with Vir’s infectious disease expertise
  • Vir will be responsible for all development and commercialization of any selected DCs while Alnylam has an option to share equal profits & losses and may get development & commercialization milestones and royalties on sales of products resulting from the collaboration
  • As per the expanded collaboration, companies can develop up to six novel siRNAs to treat infectious diseases. The partners are currently working on VIR-2218 (ALN-HBV02) for HBV, which is being evaluated in P-I/II study and is the first program to enter the clinic as a part of the infectious disease collaboration

Click here to­ read full press release/ article | Ref: Alnylam | Image: VIR

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post